Cold Urticaria Clinical Trials

Find Cold Urticaria Clinical Trials Near You

Identification of Circadian Rhythm Deregulation in Patients With Cryopyrin-associated Periodic Syndrome (CAPS)

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other, Device, Biological, Genetic
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity. * In the main loop, the BMAL1 transcription factor links with CLOCK or NPAS2 ( (Neuronal PAS Domain Protein 2) to activate transcription of per1,2 and 3 and cryptochrome (cry1 and cry2), which in turn repress BMAL1/CLOCK1 transcriptional activity.. The BMAL1/CLOCK complex also activates transcription of numerous target genes (per and cry, Rev-erb, etc.).. * other secondary loops refine the function of the first. Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome. Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined. The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: t
View:

⁃ Patient with CAPS group :

• Patients aged 6 and over

• Participant with CAPS confirmed by NLRP3 genetic analysis

• Weight greater than or equal to 25 Kg

• Parents/guardians who have been informed of the study and have signed a consent form.

• Patient affiliated to a social security scheme

⁃ Control group (healthy participant):

• Participant aged 6 and over

• Weight greater than or equal to 25 Kg

• Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol

• Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis

• Parents/guardians who have been informed of the study and have signed a consent form.

• Participant who has been informed of the study and has agreed to take part

• Participant affiliated to a social security scheme

Locations
Other Locations
France
Hôpital Femme-Mère-Enfant (HCL)
RECRUITING
Bron
Hôpital Claude Huriez (CHU de Lille)
NOT_YET_RECRUITING
Lille
Hôpital de la Croix-Rousse (HCL)
NOT_YET_RECRUITING
Lyon
Hôpital Edouard Herriot (HCL)
NOT_YET_RECRUITING
Lyon
Hôpital Kremlin-Bicêtre (AP-HP)
NOT_YET_RECRUITING
Paris
Hôpital Tenon (AP-HP)
NOT_YET_RECRUITING
Paris
Contact Information
Primary
Alexandre Alexandre, PR
Alexandre.belot@chu-lyon.fr
04 27 85 61 26
Backup
Samira Plassart
Samira.plassart@chu-lyon.fr
04 27 85 54 42
Time Frame
Start Date: 2026-02-25
Estimated Completion Date: 2029-02-25
Participants
Target number of participants: 30
Treatments
Active_comparator: Patients with cryopyrin-associated periodic syndrome (CAPS)
Confirmed by genetic analysis of NLRP3
Placebo_comparator: Control group
Healthy participant (absence of CAPS, verified by NLRP3 gene analysis) living in the same household as a CAPS participant included in the protocol
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.